Folprecht, Gunnar <br/><br/>
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.  [electronic resource] 

 -  The Lancet. Oncology  Jan 2010 
 - 38-47 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(09)70330-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Austria<br/>Camptothecin--adverse effects<br/>Cetuximab<br/>Chemotherapy, Adjuvant<br/>Colorectal Neoplasms--pathology<br/>ErbB Receptors--analysis<br/>Female<br/>Fluorouracil--adverse effects<br/>Germany<br/>Hepatectomy<br/>Humans<br/>Leucovorin--adverse effects<br/>Linear Models<br/>Liver Neoplasms--chemistry<br/>Magnetic Resonance Imaging<br/>Male<br/>Middle Aged<br/>Mutation<br/>Neoadjuvant Therapy<br/>Odds Ratio<br/>Organoplatinum Compounds--adverse effects<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>Retrospective Studies<br/>Risk Assessment<br/>Time Factors<br/>Tomography, Spiral Computed<br/>Treatment Outcome<br/>ras Proteins--genetics